Literature DB >> 31390292

Acute Care Utilization at End of Life in Sickle Cell Disease: Highlighting the Need for a Palliative Approach.

Emily E Johnston1,2,3, Oyebimpe O Adesina4, Elysia Alvarez5, Heather Amato6, Susan Paulukonis6, Ashley Nichols7, Lisa J Chamberlain8, Smita Bhatia2,3.   

Abstract

Background: People with sickle cell disease (SCD) have a life expectancy of <50 years, so understanding their end-of-life care is critical. Objective: We aimed to determine where individuals with SCD were dying and their patterns of care in the year preceding death to highlight end-of-life research priorities and possible opportunities for intervention. Design: Using the California SCD Data Collection Program database (containing administrative data, vital records, and Medicaid claims), we examined people with SCD who died between 2006 and 2015 (cases) at age <80 years and examined their hospital and emergency department (ED) utilization in their last year of life. Comparators included living controls with SCD matched 1:1 based on age, analysis year, insurance, and income.
Results: We identified 486 people with SCD (cases) who died at a median age of 45 years (SD: 16 years). Most died in the hospital (63%) and ED (15%). In their last year of life, people with SCD were hospitalized for an average of 42 days (SD: 49 days) over five admissions. Inpatient admissions and ED visits were stable throughout the year until the month before death when acute care utilization sharply increased. In their last year of life, cases had more hospitalizations than controls, but similar ED utilization. Conclusions: People with SCD are dying acutely at a young age and most die in the hospital and the ED. Since clinicians caring for people with SCD currently cannot predict which acute events may be life-threatening, a comprehensive palliative approach to people with SCD must extend beyond chronic pain management and psychosocial support to include advance care planning.

Entities:  

Keywords:  end-of-life; medical intensity; sickle cell; utilization

Mesh:

Year:  2019        PMID: 31390292     DOI: 10.1089/jpm.2018.0649

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  6 in total

1.  Understanding sickle cell disease: impact of surveillance and gaps in knowledge.

Authors:  Mandip Kaur; Mary Brown; Ted W Love; Alexis Thompson; Marsha Treadwell; Kim Smith-Whitley
Journal:  Blood Adv       Date:  2020-02-11

2.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

3.  Thinking globally to improve care locally: A Delphi study protocol to achieve international clinical consensus on best-practice end-of-life communication with adolescents and young adults with cancer.

Authors:  Ursula M Sansom-Daly; Lori Wiener; Anne-Sophie Darlington; Hanneke Poort; Abby R Rosenberg; Meaghann S Weaver; Fiona Schulte; Antoinette Anazodo; Celeste Phillips; Louise Sue; Anthony R Herbert; Jennifer W Mack; Toni Lindsay; Holly Evans; Claire E Wakefield
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

4.  Sickle cell disease and COVID-19 in pregnant women.

Authors:  Kamila Kolanska; Radostina Vasileva; François Lionnet; Aline Santin; Suha Jaudi; Yohann Dabi; Nathalie Chabbert-Buffet; Emile Daraï; Marie Bornes
Journal:  J Gynecol Obstet Hum Reprod       Date:  2022-01-29

5.  Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study.

Authors:  Eberechi Nwogu-Onyemkpa; Deepa Dongarwar; Hamisu M Salihu; Lois Akpati; Maricarmen Marroquin; Megan Abadom; Aanand D Naik
Journal:  BMJ Open       Date:  2022-08-16       Impact factor: 3.006

6.  Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease.

Authors:  Trisha E Wong; Jhaqueline Valle; Susan Paulukonis
Journal:  Health Sci Rep       Date:  2021-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.